Yes, and the fact that the FDA appears to be a lot more accommodating to the need for addressing the rapid progress biotechnology in genearal is achieving lately. Perhaps the revival of "Cancer Moonshot" this year is part of that too....https://www.washingtonpost.com/health/2022/02/02/biden-cancer-moonshot-renewal/
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint
Week 45 Wrap: Combat sports usher in Trump 2.0 – or is it male insecurity?; RBA boring; Propane suggests China alive
